Oral clofarabine for relapsed/refractory non-Hodgkin lymphomas: results of a phase 1 study
about
Phase I study of oral clofarabine consolidation in adults aged 60 and older with acute myeloid leukemia.Clinical pharmacology and clinical trials of ribonucleotide reductase inhibitors: is it a viable cancer therapy?Sequential therapy combining clofarabine and T-cell-replete HLA-haploidentical haematopoietic SCT is feasible and shows efficacy in the treatment of refractory or relapsed aggressive lymphoma.
P2860
Oral clofarabine for relapsed/refractory non-Hodgkin lymphomas: results of a phase 1 study
description
2013 nî lūn-bûn
@nan
2013 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
name
Oral clofarabine for relapsed/ ...... as: results of a phase 1 study
@ast
Oral clofarabine for relapsed/ ...... as: results of a phase 1 study
@en
type
label
Oral clofarabine for relapsed/ ...... as: results of a phase 1 study
@ast
Oral clofarabine for relapsed/ ...... as: results of a phase 1 study
@en
prefLabel
Oral clofarabine for relapsed/ ...... as: results of a phase 1 study
@ast
Oral clofarabine for relapsed/ ...... as: results of a phase 1 study
@en
P2093
P2860
P1433
P1476
Oral clofarabine for relapsed/ ...... as: results of a phase 1 study
@en
P2093
David C Fisher
Donna S Neuberg
Ephraim P Hochberg
Eric D Jacobsen
Jeffrey A Barnes
Jennifer R Brown
Ronald W Takvorian
P2860
P304
P356
10.3109/10428194.2013.763397
P577
2013-01-30T00:00:00Z